ASCO GICS 2022

CME

Expert Analysis: CCO Independent Conference Highlights of the 2022 ASCO Gastrointestinal Cancers Symposium (GICS)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 20, 2022

Expiration: April 19, 2023

Manish A. Shah
Manish A. Shah, MD
Rachna Shroff
Rachna Shroff, MD, MS

Activity

Progress
1
Course Completed
Key Studies from ASCO Gastrointestinal Cancers Symposium 2022

In this module, Manish A. Shah, MD, and Rachna Shroff, MD, review and discuss the clinical implications of key studies presented at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (GICS). The studies covered treatments for patients with rectal, gastric/gastroesophageal junction, liver, hepatobiliary tract, and pancreas cancers in both frontline and later settings.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with gastrointestinal (GI) cancers do you provide care for in a typical month?

At GICS 2022, Lumish and colleagues reported early data for neoadjuvant PD-1 blockade with dostarlimab with or without chemoradiotherapy in patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (MMRd) stage II/III rectal cancer. All of the following findings were reported from this study EXCEPT which one?

At GICS 2022, Sun and colleagues reported updated results from the phase III KEYNOTE-590 trial of pembrolizumab plus chemotherapy (CT) vs placebo plus CT in patients with esophageal cancer. A colleague asks you to share insights from that study potentially impacting clinical practice. You will mention that, after 12 additional months of follow-up (median of approximately 35 months), investigators reported which of the following for pembrolizumab plus CT vs placebo plus CT?

The global, multicenter phase III TOPAZ-1 study evaluated durvalumab plus gemcitabine and cisplatin (GemCis) vs placebo plus GemCis in patients with locally advanced or metastatic biliary tract cancer. Which of the following patient subgroups was reported to achieve an OS benefit with the addition of durvalumab to CT in this study?

A 43-year-old patient with relapsed pancreatic cancer asks you about available clinical trial options. You mention that she may qualify for clinical trials evaluating the KRAS inhibitors adagrasib or sotorasib if her tumor has which of the following KRAS mutations?